Fina Biosolutions

Fina Biosolutions is a private biotechnology company that provides critical enabling technologies and services for the development and manufacturing of conjugate vaccines. Its core offerings include proprietary conjugation chemistry, recombinant carrier proteins (notably CRM197), functionalized dextrans, and extensive consulting and laboratory services aimed at reducing vaccine costs. The company, led by founder and renowned scientist Dr. Andrew Lees, positions itself as a strategic partner for biotech firms and vaccine manufacturers worldwide, especially those targeting pneumococcal and meningococcal diseases in emerging markets.

Proprietary bioconjugation chemistry, recombinant carrier protein (CRM197, rTTHc) production platform, and expertise in functionalized polysaccharide (dextran) chemistry for vaccine development and research tools.

Fina competes with large contract research organizations (CROs) offering bioconjugation services and other suppliers of carrier proteins (e.g., Pfizer for CRM197). Its differentiation lies in its deep, specialized expertise in conjugate vaccine chemistry, its focus on affordability for emerging markets, and its proprietary recombinant protein and dextran technologies.